Delivery Order SPE2DB20D3103-SPE2DB25FP6D2
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $1,117.48 by the Defense Logistics Agency (DLA) on August 7, 2025, for the supply of Xeomin 100 Unit Vials. This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 28, 2025, and represents a child order under a larger contract vehicle. The award carries no set-aside designation, reflecting open...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $93,868.32 by the Defense Logistics Agency's Medical Supply Chain for the supply of Xeomin 200 Unit Vials. The contract, awarded on August 7, 2025, represents a firm fixed price delivery order with an ultimate completion date of August 28, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This award was competitively awarded with no...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency for 100-unit vials of Xeomin, a botulinum toxin product used for medical purposes, valued at $3,352.44. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 21, 2025. Performance will occur at the contractor's Corporate Office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its primary...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $14,806.61 by the Defense Logistics Agency's Medical Supply Chain on July 31, 2025, for the supply of XEOMIN 100 UT vials. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 27, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is...
- The Defense Logistics Agency awarded a $12,851.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The contract, awarded on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX). The company...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,984.25 for 100-unit vials of Xeomin on July 28, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract, which carries no set-aside designation, will be performed in Conshohocken, Pennsylvania, where the vendor maintains its corporate headquarters. Xeomin is a botulinum toxin product used for therapeutic and cosmetic applications, and this delivery order represents a...
- The Defense Logistics Agency awarded a $6,704.88 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin injection used in medical and therapeutic applications. This firm fixed price delivery order, issued on August 7, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xeomin 200 Unit Vials, a botulinum toxin product used for medical purposes. This firm fixed price delivery order, valued at approximately $25.1K, is scheduled for completion by August 21, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The contract was competitively awarded with no set-aside designation, reflecting the vendor's established...
- Amerisourcebergen Drug Corp has been awarded a firm fixed price delivery order by the Defense Logistics Agency (DLA) Troop Support Medical to supply 200 unit vials of Xeomin, a botulinum toxin type A, in support of military treatment programs. Valued at $26,212.50, the delivery order was issued against an indefinite delivery contract vehicle and requires performance be completed by December 28, 2023 at Amerisourcebergen's facility in Conshohocken, Pennsylvania. No set aside designation was...
- The Defense Logistics Agency awarded a $1,215.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 50-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This non-set-aside contract was competitively awarded with an ultimate completion date of August 28, 2025, and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP6D2Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 23, 2025, for the supply of Xeomin 100 unit vials. The contract is valued at $2,793.70 and carries a firm fixed price structure with an ultimate completion date of August 13, 2025. This non-set-aside award represents a competitive procurement action and will be performed at the contractor's Conshohocken facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026 that provides comprehensive global pharmaceutical support for military healthcare programs worldwide. Xeomin is a prescription botulinum toxin product used for medical and cosmetic applications, and this procurement supports the Defense Health Agency's pharmaceutical supply needs. AmerisourceBergen's extensive federal contract portfolio demonstrates its critical role as a supplier of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains for military and veteran healthcare systems. The contract award reflects the company's demonstrated capability to meet federal procurement requirements through open competition and its established position within the DLA's pharmaceutical supply chain supporting U.S. military operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 7/23/25 |